*It may take a few minutes for the email to arrive.
**Be sure to check your spam/junk folder.
You can be eating “clean,” moving your body, and doing all the right things, then a routine blood test hits you with a cholesterol surprise.
If that’s you, take a breath. A cholesterol shift in the menopause transition is common, biologically driven, and often under-discussed. Menopause is also a key moment to get serious (not scared) about heart health, because cardiovascular disease remains the leading cause of death for women in the U.S.
This is your HotPause Health guide to what’s happening, what to test, and the evidence-based steps that actually move the needle.
Cholesterol is a waxy substance your body uses to build hormones, vitamin D, and cell membranes. The problem isn’t cholesterol existing, it’s cholesterol particles building up in artery walls over time, increasing the risk of heart attack and stroke.
A standard lipid panel typically includes:
For most adults, a commonly cited “desirable” total cholesterol level is under 200 mg/dL (individual targets vary based on risk).
Before menopause, women often have a more favorable lipid profile than men of the same age. After menopause, that advantage narrows…quickly.
Estrogen influences lipid metabolism, largely through effects on the liver and lipid handling. When estrogen drops, the lipid profile can shift in a more atherogenic direction (more “plaque-forming”).
Unlike symptoms that may build gradually in perimenopause, lipid changes often cluster around the final menstrual period, with atherogenic changes occurring within about one year of the final period in some datasets.
Research consistently shows that after menopause, many women experience:
In recent reviews, menopause has been associated with increases in total cholesterol on the order of ~10–14% and LDL increases on the order of ~10–20 mg/dL in some summaries, though magnitude varies by population and baseline risk.
High cholesterol usually has no symptoms. That’s why it’s easy to miss during a life stage already packed with real symptoms (sleep disruption, hot flashes, mood changes, fatigue, and “why is my body doing this?”).
Bottom line: If you don’t test, you don’t know.
Start with a standard lipid panel
For adults at low risk, the American Heart Association notes cholesterol testing about every 4–6 years (more often if risk changes). In perimenopause/menopause, “risk changes” is the point, so it’s reasonable to review your timing with your clinician.
Consider “advanced” risk markers when it’s clinically helpful
Not everyone needs extra testing. But if your cholesterol has jumped, you have a family history, you carry excess weight, your triglycerides are elevated, you have metabolic syndrome/insulin resistance, or your risk feels underestimated, these can be useful discussion points:
1) Don’t default to self-blame
A menopause-related cholesterol rise can happen even when lifestyle hasn’t changed much. Hormones are part of the equation. Your job is to respond strategically, not spiral.
2) Build a heart-forward lifestyle (without going to extremes)
You do not need to become a marathoner or live on kale. You do need consistency. Clinician-favorite levers include:
Some women will not reach target lipid levels with lifestyle alone, especially with genetic risk. Statins remain a cornerstone therapy for reducing cardiovascular risk in appropriate patients, and ACC/AHA guidelines frame lipid-lowering therapy as part of evidence-based prevention.
For some women, especially with genetics in the mix, lifestyle changes won’t be enough to bring LDL (“bad cholesterol”) down to a safer range. Statins are a well-studied, first-line tool that lower LDL and reduce cardiovascular risk for people who meet criteria.
Also important: many risk tools focus on 10-year event risk, which can understate lifetime risk in midlife women. That’s why clinicians increasingly use “risk-enhancing factors” and, in select cases, imaging like coronary artery calcium (CAC) to refine their prescription decisions.
Some women see lipid improvements on MHT. But major cardiovascular reviews note that no medical societies recommend hormone therapy solely for primary or secondary prevention of cardiovascular disease.
Translation: If you’re a candidate for MHT for menopause symptom relief, talk with a qualified clinician about the broader risk/benefit profile. But cholesterol management still typically relies on lifestyle and, when needed, lipid-lowering medication, not MHT as a “cholesterol drug.”
Perimenopause and menopause are not just about hot flashes. They’re a cardiometabolic pivot point, and cholesterol is one of the quiet ways your body signals that it’s time to adjust the strategy.
This is not about perfection. It’s about:
0